生物制品板块1月22日跌0.73%,艾迪药业领跌,主力资金净流出5.51亿元
Zheng Xing Xing Ye Ri Bao·2026-01-22 09:01

Market Overview - The biopharmaceutical sector experienced a decline of 0.73% on January 22, with Aidi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Individual Stock Performance - Wanze Co., Ltd. (000534) saw a significant increase of 6.53%, closing at 27.74 with a trading volume of 337,600 shares and a transaction value of 917 million [1] - Aidi Pharmaceutical (688488) reported a substantial decrease of 13.48%, closing at 18.17 with a trading volume of 281,700 shares and a transaction value of 537 million [2] - Other notable performers included ST Sihuan (000518) with a rise of 3.03% and Kanghong Pharmaceutical (002773) with a decline of 3.03% [1][2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 551 million from institutional investors, while retail investors saw a net inflow of 279 million [2] - The main capital inflow was observed in Wanze Co., Ltd. with 81.16 million from institutional investors, while Kanghong Pharmaceutical had a net outflow of 50.59 million from retail investors [3]

Aidea Pharma-生物制品板块1月22日跌0.73%,艾迪药业领跌,主力资金净流出5.51亿元 - Reportify